Hyperactivité vésicale idiopathique : efficacité et tolérance des traitements pharmacologiques : revue de la littérature

Moyson, J.; Legrand, Fanny; Bossche, Marc Vanden; Quackels, Thierry; Roumeguère, Thierry

doi:10.1016/j.purol.2016.12.011

Cited by 8 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect on nocturia was very limited or non-existent. [22][23][24] Some studies, including metaanalysis and head-to-head trials, comparing antimuscarinic drugs showed some advantages of solifenacin over tolterodine ER and fesoterodine over tolterodine ER. 20,[25][26][27] A placebo control study, evaluating darifenacin clinical efficacy, concluded that, although having better efficacy than placebo, the results showed similar efficacy to placebo-controlled studies enrolling other antimuscarinics.…”

Section: Antimuscarinics (Anticholinergic Drugs)mentioning

confidence: 99%

Pharmacology of the lower urinary tract: update on LUTS treatment

Abreu-Mendes

Silva

Cruz

2020

Therapeutic Advances in Urology

View full text Add to dashboard Cite

The number of compounds used in the pharmacological treatment of lower urinary tract symptoms (LUTS) of patients who do not respond to conservative measures has been relatively stable during the last decade, with the exception of the introduction of the new class of β3 adrenoceptor agonists. However, different combinations have been investigated, and the long-term use of these compounds has raised new concerns about adherence and safety. This review summarizes the current state of pharmacology for LUTS, and presents a thorough discussion of the possible challenges concerning their future use. In this narrative review, we analyze the most recent articles related to LUTS pharmacotherapy, after an initial review of mechanisms of bladder function relevant in present clinical practice. The main problems with pharmacotherapy in LUTS are associated with its moderate efficacy, low persistence on treatment, and the incidence of short- and long-term adverse events (AE) associated with some compounds. The long-term AE, such as cognitive impairment in the elderly vulnerable patients associated with antimuscarinic drugs or persistent erectile dysfunction in sexually active men after treatment with 5-α-reductase inhibitors (5-ARI), are some of the problems addressed in this review. Combination therapy taking advantage of the synergistic mechanisms of action between some classes of compounds may overcome AE associated with dose escalation. LUTS pharmacotherapy offers moderate results to most patients but not a full cure. The use of combination drugs to achieve better clinical results, reduce AE and improve both efficacy and adherence, will be used more frequently in the future. The recently raised concern on potential long-term irreversible AE associated with some of these drugs, like antimuscarinics and 5-ARI, are critically important and require further investigation.

show abstract

Section: Antimuscarinics (Anticholinergic Drugs)mentioning

confidence: 99%

Pharmacology of the lower urinary tract: update on LUTS treatment

Abreu-Mendes

Silva

Cruz

2020

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…Tous les anticholinergiques ont prouvé leur efficacité clinique par rapport au placebo (42)(43)(44)(45)(46). Il faut toutefois souligner que les critères de jugement de ces études étaient le plus souvent le nombre de mictions par 24h ainsi que le nombre d'épisodes d'incontinence urinaire par urgenturie.…”

Section: Les Mesures Comportementales Et Hygiéno-diététiquesunclassified

“…L'efficacité modeste de ces traitements et leurs effets secondaires font que le taux d'arrêt de traitement est élevé avec seulement 36% des patients qui poursuivent le traitement à un an (48). La plupart des méta-analyses rapportées souligne un effet modeste de ces traitements même si la satisfaction des patients était plutôt élevée (42,44). Malheureusement, très peu d'études ont comparé l'efficacité de deux anticholinergiques, deux dosages ou deux formulations entre elles.…”

Section: Les Mesures Comportementales Et Hygiéno-diététiquesunclassified

Traitement de première intention du syndrome clinique d’hyperactivité vésicale non neurologique

Gamé

Phé

2020

Progrès en Urologie

View full text Add to dashboard Cite

“…De nombreuses études contrôlées ont montré l'efficacité de la toxine botulique A sur le syndrome clinique d'hyperactivité vésicale réfractaire [43]. Le tableau 4 présente les études contrôlées ayant conduit à l'enregistrement.…”

Section: Les Injections Intradétrusoriennes De Toxine Botuliqueunclassified

Traitement du syndrome clinique d’hyperactivité vésicale non neurologique réfractaire

Gamé

Phé

2020

Progrès en Urologie

View full text Add to dashboard Cite

Hyperactivité vésicale idiopathique : efficacité et tolérance des traitements pharmacologiques : revue de la littérature

Cited by 8 publications

References 44 publications

Pharmacology of the lower urinary tract: update on LUTS treatment

Pharmacology of the lower urinary tract: update on LUTS treatment

Traitement de première intention du syndrome clinique d’hyperactivité vésicale non neurologique

Traitement du syndrome clinique d’hyperactivité vésicale non neurologique réfractaire

Contact Info

Product

Resources

About